Dr. Basel Assaf is a double-board-certified veterinary pathologist, toxicologist, and the Vice President of Toxicology and Pathology at Attentive Science Ltd. A strategic catalyst in gene therapy for over 15 years, he specializes in advancing therapeutics from early discovery to the clinic. By applying agile, mechanism-based nonclinical strategies, he optimizes development efficiencies to accelerate timelines and lower costs, successfully delivering 6 INDs to date. His career includes leading Sanofi's nonclinical safety strategy for its entire gene therapy portfolio, alongside key roles at Pfizer and the US FDA.